EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics ("the Company"). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing ...

Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series A funding. The company is developing an easy-to-use ...

Elon Musk has said that he used ketamine as a treatment in the past, but he denied reports that he was taking it frequently ...

While its effectiveness is still being researched, clinical therapists across the country and here at Bryan Medical say it’s mostly beneficial for treatment-resistant depression patients.

The field is expanding quickly, and often without clear rules. Though the FDA has approved one ketamine-based nasal spray for depression, most clinics offer intravenous infusions of ketamine, an ...

The universe of mental health clinics offering ketamine, an anesthetic with mind-bending effects, is expanding as New Yorkers ...

The federal government has bankrolled the use of an artificial ketamine nasal spray to combat treatment-resistant depression, further opening the door for dissociative and psychedelic mental ...

A nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment cheaper for thousands of Australians. It is the first new depression medication ...

The nasal spray had to go through many rounds of clinical testing, with some shown to improve depression, while others showed no improvement over a placebo. In 2019, the FDA approved Spravato for ...

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...